The impact of ivermectin on COVID-19 outcomes: a systematic review and meta-analysis DOI Open Access

Nithin Sai Yengu,

Abdul Raheem,

Andrea Gómez Pons

et al.

Annals of Medicine and Surgery, Journal Year: 2024, Volume and Issue: 87(2), P. 809 - 829

Published: Dec. 11, 2024

The COVID-19 pandemic, resulting in approximately seven million deaths globally, underscores the urgency for effective treatments. Ivermectin, among several repurposed drugs, garnered interest due to its antiviral properties. However, conflicting evidence from observational studies and randomized controlled trials raised questions about efficacy safety. This systematic review meta-analysis followed MOOSE PRISMA guidelines. Comprehensive searches were conducted databases including Scopus, Embase, PubMed, Web of Science up April 2024. Data extracted independently by two reviewers analyzed using Meta-Analysis V3 software. Across 33 encompassing 15,376 participants, ivermectin showed no significant impact on critical outcomes such as mortality [risk ratio (RR) 0.911, 95% confidence intervals (CI) 0.732-1.135], mechanical ventilation (RR 0.727, CI 0.521-1.016), polymerase chain reaction conversion 1.024, 0.936-1.120), ICU admissions 0.712, 0.274-1.850), or hospitalization rates 0.735, 0.464-1.165) compared controls. it significantly reduced time symptom alleviation (standardized mean difference -0.302, -0.587 -0.018) sustained relief 0.897, 0.873-0.921). Adverse event (AE) similar between control groups 0.896, 0.797-1.007). Meta-regression indicated older age diabetes predictors AEs. Despite observed benefits management, did not influence clinical patients. These findings highlight importance continued research identify treatments COVID-19, emphasizing need high-quality with robust methodology inform practice public health policy effectively.

Language: Английский

Inhalable spray-dried dry powders combining ivermectin and niclosamide to inhibit SARS-CoV-2 infection in vitro DOI

Catherine K. Su,

Tushar Saha,

Shubhra Sinha

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125302 - 125302

Published: Jan. 1, 2025

Language: Английский

Citations

1
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial DOI Creative Commons
Victoria Harris, Jane Holmes,

Oghenekome A. Gbinigie-Thompson

et al.

The Lancet Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

Citations

6
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity DOI Creative Commons
Sunil J. Wimalawansa

Heliyon, Journal Year: 2024, Volume and Issue: 10(15), P. e34691 - e34691

Published: July 18, 2024

The original COVID-19 vaccines, developed against SARS-CoV-2, initially mitigated hospitalizations. Bivalent vaccine boosters were used widely during 2022-23, but the outbreaks persisted. Despite this, hospitalizations, mortality, and involving dominant mutants like Alpha Delta increased winters when population's vitamin D levels at their lowest. Notably, 75 % of human immune cell/system functions, including post-vaccination adaptive immunity, rely on adequate circulatory levels. Consequently, hypovitaminosis compromises innate responses, heightening susceptibility to infections complications. vaccines primarily target SARS-CoV-2 Spike proteins, thus offering only a limited protection through antibodies. mRNA such as those for COVID-19, fail generate secretory/mucosal immunity-like IgG rendering them ineffective in halting viral spread. Additionally, mutations binding domain reduce recognition by vaccine-derived antibodies, leading evasion mutant viruses Omicron variants. Meanwhile, repeated administration bivalent intended enhance efficacy resulted immunoparesis recipients. As result, relying solely outbreak prevention, it became less effective. Dominant variants exhibit affinity angiotensin-converting enzyme receptor-2, enhancing infectivity reducing virulence. spike protein-related do not impact potency available, repurposed early therapies, ivermectin. With re-emergence impending coronaviral pandemics, regulators health organizations should proactively consider approval strategic use cost-effective adjunct therapies mentioned above counter loss emerging novel coronaviruses eliminate vaccine- anti-viral agents-related serious adverse effects. Timely implementation these strategies could morbidity, healthcare costs provide rational approach address future epidemics pandemics. This perspective critically reviews relevant literature, providing insights, justifications, viewpoints into how scientific community authorities can leverage this knowledge cost-effectively.

Language: Английский

Citations

4
Evaluating the Role of COVID-19 Vaccines in Patient Outcomes DOI

Fateme Raisi Sarbijan,

Niloofar Farsiu, Sara Shafieipour

et al.

Infectious Diseases in Clinical Practice, Journal Year: 2025, Volume and Issue: 33(2)

Published: Jan. 28, 2025

Abstract Background The recent SARS-CoV-2 pandemic posed a significant threat to human life. Vaccines played an unprecedented role in managing adverse outcomes, but the virus's ability mutate and produce new variants ongoing challenges. This research aimed examine association between different types numbers of doses COVID-19 vaccinations clinical demographic characteristics patients. Methods retrospective cross-sectional study was carried out on 161 patients hospitalized at Afzalipour Hospital Kerman, Iran, during eighth wave pandemic. Data features, symptoms, patient status, disease outcome, vaccination history were collected. Results Most (over 75%) had received 2 or 3 vaccine. Vaccination type number showed differences based gender ( P = 0.048) age group 0.034), respectively. Shortness breath vaccine 0.0178). Fatigue substantially differed 0.03975). There no gastrointestinal status vaccines, lower death rates observed vaccinated Additionally, while trends indicated better outcomes with higher doses, there variations blood oxygen saturation (SpO ) respiratory rate doses. Conclusions findings highlight despite reduction efficacy against emerging variants.

Language: Английский

Citations

0
Model reference adaptive control of the nonlinear fractional order – stochastic model of the corona virus DOI
Abedin Ranjbar, Ali Madady, Mehdi Ramezani

et al.

Chaos Solitons & Fractals, Journal Year: 2025, Volume and Issue: 194, P. 116225 - 116225

Published: March 1, 2025

Language: Английский

Citations

0
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole DOI Creative Commons
Shakta Mani Satyam, Mohamed El‐Tanani, Mohamed Anas Mohamed Faruk Patni

et al.

Antibiotics, Journal Year: 2025, Volume and Issue: 14(5), P. 459 - 459

Published: April 30, 2025

Background: The COVID-19 pandemic necessitated the urgent exploration of therapeutic options, including drug repurposing. Anthelmintic drugs such as ivermectin and mebendazole have garnered interest due to their potential antiviral immunomodulatory properties. However, conflicting evidence from randomized clinical trials (RCTs) necessitates a comprehensive meta-analysis determine efficacy safety in management. Objective: This evaluates treating by analyzing impact on viral clearance, symptom resolution, hospitalization duration, profiles. Methods: A systematic search Scopus, PubMed, Embase, Cochrane Library was conducted following PRISMA guidelines identify RCTs published up February 2025. Eligible studies included adult patients with confirmed who received or compared placebo standard care. Data extraction risk bias assessment were performed using Risk Bias Tool. Statistical heterogeneity evaluated I2 statistic, pooled effect sizes calculated for primary outcomes. Results: Twenty-three (n = 12,345) included, twenty-one two mebendazole. analysis suggested no statistically significant improvement clearance (p 0.39), duration 0.15), resolution 0.08) individual indicated benefits, particularly mebendazole, reducing load inflammation. Both exhibited favorable profiles, increase adverse events. Conclusions: promising propensities observed selected underscore adjunct therapies COVID-19. With well-established effects, affordability, these present strong candidates further exploration. Advancing research through well-designed, large-scale will help unlock full expand treatment options fight against

Language: Английский

Citations

0
Effectiveness of non-pharmaceutical interventions as implemented in the UK during the COVID-19 pandemic: a rapid review DOI Creative Commons
Thulani Ashcroft, Emilie McSwiggan, Eldad Agyei‐Manu

et al.

Journal of Public Health, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Although non-pharmaceutical inventions (NPIs) were used globally to control the spread of COVID-19, their effectiveness remains uncertain. We aimed assess evidence on NPIs as implemented in UK, allow public health bodies prepare for future pandemics. rapid systematic methods (search date: January 2024) identify, critically appraise and synthesize interventional, observational modelling studies reporting NPI UK. Eighty-five modelling, nine three interventional included. Modelling had multiple quality issues; six 12 non-modelling high quality. The best available was test release strategies case contacts (moderate certainty), which suggestive a protective effect. school-related universal lockdown also effect, this considered low certainty. Evidence certainty remaining very or inconclusive. validity reliability UK during COVID-19 pandemic is weak. To improve generation support decision-making pandemics other emergencies, it essential build evaluation into design interventions.

Language: Английский

Citations

0
Ivermectin-induced toxicity in HepG2 cells and the protective effect of tetrahydrocurcumin and vitamin C DOI
Camila Araújo Miranda,

João Rodolfo Domingues Mansano,

Fábio E. Mingatto

et al.

Drug and Chemical Toxicology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 11

Published: Aug. 19, 2024

Ivermectin (IVM) is a semi-synthetic antiparasitic derived from abamectin, one of the natural avermectins. The liver promotes metabolism and excretion IVM, representing risk toxicity to this organ. use antioxidants alleviate damage caused by chemicals has been increasingly studied. Thus, aim study was evaluate effects IVM on HepG2 cells elucidate mechanisms related its possible protection provided tetrahydrocurcumin (THC) vitamin C. were treated with (1-25 μM) for 24 48 h. cytotoxic cells, denoted dose-dependent decrease in cell proliferation metabolic activity. In addition, induced membrane at all tested concentrations both incubation times. significantly decreased mitochondrial potential 5 μM (24 h) 1 (48 h). Additionally, showed time- cellular adenosine triphosphate levels. levels reduced glutathione manner, while stimulated production reactive oxygen nitrogen species (RONS) doses, reaching rates above 50% following treatment 7.5 or Treatment THC (50 C protected against IVM-induced cytotoxicity RONS production. These results suggest that oxidative involved can mitigate toxic compound.

Language: Английский

Citations

2
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes DOI Creative Commons
Richard Hobbs,

Oghenekome A. Gbinigie-Thompson,

Milensu Shanyinde

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 89(4), P. 106248 - 106248

Published: Aug. 29, 2024

Evidence for the effect of favipiravir treatment acute COVID-19 on recovery, hospital admissions and longer-term outcomes in community settings is limited.

Language: Английский

Citations

1
Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses DOI Creative Commons
David Scheim, Peter Parry, David J. Rabbolini

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(4), P. 647 - 647

Published: April 22, 2024

Consistent with the biochemistry of coronaviruses as well established over decades, SARS-CoV-2 makes its initial attachment to host cells through binding spike protein (SP) sialylated glycans (containing monosaccharide sialic acid) on cell surface. The virus can then slide and enter via ACE2. SP attaches particularly tightly trillions red blood (RBCs), platelets endothelial in human body, each very densely coated acid surface molecules but having no ACE2 or minimal These interlaced attachments trigger aggregation, microvascular occlusion vascular damage that underlie hypoxia, clotting related morbidities severe COVID-19. Notably, two betacoronaviruses express a acid-cleaving enzyme are benign, while other three—SARS, MERS—are virulent. RBC aggregation experimentally induced several animal species using an injected polysaccharide caused most same This glycan is key disentangling controversies have arisen efficacy certain generic COVID-19 treatment agents safety SP-based vaccines. More broadly, disregard for active physiological role RBCs yields unreliable erroneous reporting pharmacokinetic parameters routinely obtained drugs bioactive detection plasma, whole-blood levels being up 30-fold higher. Appreciation elucidate underpinnings health conditions, including cardiovascular disease, therapeutic opportunities address them.

Language: Английский

Citations

1